Link Between Bone Medications and Serious Jawbone Disease Identified
New research reveals a significant link between antiresorptive bone medications, especially denosumab, and the risk of developing osteonecrosis of the jaw, highlighting the importance of careful management and oral health monitoring.
Recent research by the University of Oulu has highlighted important safety considerations regarding medications used to treat bone conditions. Specifically, certain drugs, especially when combined with corticosteroids, significantly elevate the risk of developing osteonecrosis of the jaw—a condition where the jawbone deteriorates and becomes fragile. This condition, although rare, poses serious health risks.
The study, which analyzed medical data from nearly 60,000 Finnish adult patients who started bone-related treatments between 2013 and 2015, found that the incidence of osteonecrosis was about 0.3% among those on low doses of antiresorptive (AR) drugs and increased dramatically to 9% among high-dose AR users. Antiresorptive drugs like denosumab and bisphosphonates are commonly prescribed in Finland for osteoporosis management and to prevent bone metastases in cancer patients, such as those with breast or prostate cancer.
Key findings revealed that denosumab users faced a significantly higher risk—up to five times more—of developing serious jawbone damage compared to bisphosphonate users. The risk further escalates when corticosteroids are used concurrently; in these cases, the likelihood of osteonecrosis doubles for high-dose AR patients and increases sixfold for those on low doses. Additional vulnerable groups include males and individuals diagnosed with cancer.
This pioneering population-level study underscores the importance of cautious medication management, especially for patients on multiple drugs affecting bone health. Clinicians are urged to closely monitor patients, particularly when prescribing denosumab or corticosteroids together, and to emphasize oral health care by assessing teeth and gums before and during treatment.
In conclusion, while antiresorptive medications are effective for managing bone diseases, their potential serious side effects require careful attention. Patients should consult healthcare providers about their specific treatments and ensure regular dental check-ups to mitigate risks.
Source: https://medicalxpress.com/news/2025-06-common-bone-medications-linked-jaw.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Calling for Cultural Shift to Reduce Burnout in Pharmacy Education
A recent study highlights the urgent need for cultural change in pharmacy education to address faculty burnout and improve workplace support, emphasizing tailored strategies and ongoing interventions.
Advancements in Diagnostic Tools for Adult ADHD Detection
Research at the University of Oslo is advancing diagnostic tools to better detect ADHD in adults by studying mind wandering and brain activity patterns, aiming to improve diagnosis and treatment options.
Bariatric Surgery May Improve Outcomes for Obese Patients with Inflammatory Bowel Disease
New research reveals that bariatric surgery can significantly improve inflammatory bowel disease outcomes in obese patients, offering a promising integrated treatment approach.
Polio Near Eradication: Challenges of Fake Records, Vaccine Limitations, and Missteps
Global polio eradication efforts have made significant progress, but fake records, vaccine risks, and logistical missteps threaten these gains. Learn about the ongoing struggle to eliminate this crippling disease.